Natural product derived privileged scaffolds in drug discovery

EK Davison, MA Brimble - Current opinion in chemical biology, 2019 - Elsevier
The biological activity and structural diversity of natural products are unsurpassed by any
available synthetic screening libraries. As such, these privileged scaffolds serve as …

Nitric oxide donor-based cancer therapy: advances and prospects

Z Huang, J Fu, Y Zhang - Journal of medicinal chemistry, 2017 - ACS Publications
The increasing understanding of the role of nitric oxide (NO) in cancer biology has
generated significant progress in the use of NO donor-based therapy to fight cancer. These …

Recent advances (2015–2016) in anticancer hybrids

N Kerru, P Singh, N Koorbanally, R Raj… - European journal of …, 2017 - Elsevier
In spite of the development of a large number of novel anticancer drugs over the years,
Cancer remains as a prominent cause of death, worldwide. Numerous drugs that are …

[HTML][HTML] Oridonin and its derivatives for cancer treatment and overcoming therapeutic resistance

X Liu, J Xu, J Zhou, Q Shen - Genes & diseases, 2021 - Elsevier
Cancer is one of the diseases with high morbidity and mortality on a global scale.
Chemotherapy remains the primary treatment option for most cancer patients, including …

Recent advances in berberine inspired anticancer approaches: from drug combination to novel formulation technology and derivatization

S Habtemariam - Molecules, 2020 - mdpi.com
Berberine is multifunctional natural product with potential to treat diverse pathological
conditions. Its broad-spectrum anticancer effect through direct effect on cancer cell growth …

Recent advances in oridonin derivatives with anticancer activity

PJM Sobral, ATS Vicente, JAR Salvador - Frontiers in Chemistry, 2023 - frontiersin.org
Cancer is a leading cause of mortality responsible for an estimated 10 million deaths
worldwide in 2020, and its incidence has been rapidly growing over the last decades …

Oridonin, a Promising ent-Kaurane Diterpenoid Lead Compound

D Li, T Han, J Liao, X Hu, S Xu, K Tian, X Gu… - International Journal of …, 2016 - mdpi.com
Oridonin belongs to ent-kaurane tetracyclic diterpenoid and was first isolated from Isodon
species. It exhibits inhibitory activities against a variety of tumor cells, and pharmacological …

Identification of a potent oridonin analogue for treatment of triple-negative breast cancer

H Yao, S Xie, X Ma, J Liu, H Wu, A Lin… - Journal of Medicinal …, 2020 - ACS Publications
Triple-negative breast cancer (TNBC) is one of the most highly invasive and metastatic
breast cancers without safe and effective therapeutic drugs. The natural product oridonin is …

Synthesis and biological evaluation of novel Jiyuan Oridonin A-1, 2, 3-triazole-azole derivatives as antiproliferative agents

Y Ke, JJ Liang, RJ Hou, MM Li, LF Zhao… - European Journal of …, 2018 - Elsevier
As a continuation of our research on developing potent and potentially safe anti-proliferative
agents, two series of novel Jiyuan Oridonin A-1, 2, 3-triazole-azole hybrids were designed …

Design, synthesis and biological evaluation of novel nitric oxide-donating protoberberine derivatives as antitumor agents

J Chen, T Wang, S Xu, A Lin, H Yao, W Xie… - European journal of …, 2017 - Elsevier
A novel class of NO-donating protoberberine derivatives were synthesized and initially
evaluated for their anti-hepatocellular carcinoma activities. Most of the compounds exhibited …